Tosk has one patented drug in human trials, another on track for trials planned for 2018, and two others under development.


Tosk has patented two new pharmaceutical products and has two other research-stage products in development.

TK:90: Our most advanced patented drug is TK-90 for mucositis side effect reduction. Mucositis is the painful inflammation and ulceration of the mucous membranes lining the digestive tract, usually as an adverse effect of chemotherapy or radiotherapy treatment for cancer. Mucositis can occur anywhere along the gastrointestinal tract, including the stomach, intestines, and anus. Oral mucositis, inflammation and ulceration that occurs in the mouth, is a common and often debilitating complication of cancer treatment. Mucositis in the gut can introduce a route of infection that can be debilitating and potentially fatal.

Mucositis is a common side effect of treatments for cancers of the head and neck and for leukemias. If mucositis occurs, it can be costly to treat and may force therapy to be reduced or ended.

TK-39: Tosk’s second patented product, TK-39, has been developed to block the cardiotoxicity that results from widely-used cancer drugs known as anthracyclines. This cardiotoxicity is permanent and limits the lifetime dose of these drugs. Many patients are forced to suspend treatment before the full benefit of treatment is realized due to this adverse effect. Anthracyclines are used to treat cancers such as lymphoma, lung cancer, and breast cancer.

Tosk’s CompanionTM drugs are designed to be administered along with existing cancer therapies to either eliminate their dose-limiting and potentially fatal side effects or to make certain drugs effective in patients who do not currently benefit from treatment.